Clinical Trial

REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-12; most recent amendment 2025-06-27.
Status change: Not Yet Recruiting → Recruiting 2025-05-19
Trial Details
NCT Number NCT06875986
Lead Sponsor Otsuka Pharmaceutical Co., Ltd.
Conditions Alzheimer Disease
Enrollment 200 participants
Start Date 2025-04-17
Primary Completion 2027-09-30 (estimated)
Study Completion 2028-09-23 (estimated)
Updated on ClinicalTrials.gov 2025-07-02